Pharmacopola Trybuchowscy Spółka Komandytowa (KRS 0000619909, NIP 2530338630) is a Polish company, headquartered in Resko, Zachodniopomorskie voivodeship. Pharmacopola Trybuchowscy operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since May 23, 2016. Pharmacopola Trybuchowscy's most recently reported net revenue was 62.2 M PLN for 2025.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Pharmacopola Trybuchowscy
Identity
- Name
- Pharmacopola Trybuchowscy Spółka Komandytowa
- Legal form
- SPÓŁKA KOMANDYTOWA
- Founded
- May 23, 2016
- Registry status as of
- June 30, 2026
- Latest entry
- June 30, 2026
- Founding act
- 20 MAJA 2016 R.
Articles of association history (3)
- 20 MAJA 2016 R.
- AKT NOTARIALNY Z DNIA 30 LISTOPADA 2020 R. REP. A NR 4905/2020, NOTARIUSZ MIKOŁAJ BORKOWSKI, KANCELARIA NOTARIALNA W POZNANIU - DODANO: §5 UST. 3, - ZMIENIONO: §2, §5 UST. 1, §5 UST. 2, §6 UST. 1, §7, §9.
- AKT NOTARIALNY Z DNIA 10 LUTEGO 2021 R. REP. A NR 626/2021, NOTARIUSZ BRYGIDA OŚWIĘCIMSKA, KANCELARIA NOTARIALNA W ŁOBZIE - DODANO PUNKTY: 3,4,5 W §4.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. TADEUSZA KOŚCIUSZKI, 14C, 72-315, RESKO, POLSKA
- Voivodeship
- ZACHODNIOPOMORSKIE
- District
- ŁOBESKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-27026-15153-VWUHD-21
Risk and payment profile - Pharmacopola Trybuchowscy
Credibility rating
69.7 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/10 yrs
Board changes
0
0/10 yrs
PKD changes
1
1/10 yrs
Name changes
1
1/10 yrs
Data from 10 years of registry activity.
Credibility history
Payment reliability score from 2019–2025
Current: C (70/100)
Trend: deteriorating (-2.1 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2019–2025
Current: 3.0 M PLN
Safe: 603.7 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Pharmacopola Trybuchowscy
Founded
May 23, 2016
10 years in operation
Legal form
SPÓŁKA KOMANDYTOWA
Registry: RejP
Headquarters
RESKO
ZACHODNIOPOMORSKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
N/A
Shareholders
3
shareholders
Board
2 people
Filed years
7 years
2019–2025
Registry entries
44
latest: June 30, 2026
Revenue
62.2 M PLN
2025
Net profit
2.9 M PLN
2025
Assets
14.2 M PLN
2025
Equity
5.0 M PLN
2025
EBITDA
4.1 M PLN
2025
Valuation
19.7 M PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Pharmacopola Trybuchowscy.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1m capex (+212%), a PLN 1.10 dividend three years running, Cydr Lubelski and Romanian Zarea as the premium engines
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8m of revenue and PLN 49.0m of net profit, while raising capex by 212% to PLN 48.1m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9m acquisition of a Romanian company. Despite the heavy investment cycle the board is keeping the PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7bn (+13% YoY), EBITDA of PLN 56m (+63%) and net profit of PLN 9.3m - a return to the black after a PLN 10m loss in 2024. Poland grew 31%, but CEE was under FX pressure (hryvnia -11% versus the zloty), and a weak Q4 (EBITDA -71% YoY) prompted the supervisory board to cut the 2026 EBITDA target from PLN 100m to PLN 90m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
